Krishna Institute of Medical Sciences 4Q25 Results Update

KIMS delivered a strong 4Q25 result in line with estimates, supported by a 35% yoy revenue increase and robust performance in both mature and new hospital regions.

Key Takeaways

• 1.KIMS reported 4Q results in line with expectations, with consolidated sales growing 35% yoy.
• 2.The company is projected to deliver an industry-leading topline growth of approximately 30% CAGR over FY25-28E.
• 3.KIMS is positioned to achieve top-quartile return metrics, including an RoE of roughly 25% once operations stabilize.

Table of Contents

• Mature regions steady
• New regions ramping up at a healthy pace
• Bed expansion plans
• Valuation
• Risks
• Price Target, Methodology and Risks - KRII.BO

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial